Abstract
Summary
The purpose of this plain language summary of publication is to help you understand recent findings from Part 1 of the RUBY study (full name ENGOT-EN6/GOG3031/RUBY trial).
• Researchers sometimes study new combinations of already approved individual treatments to see if the combinations work well together and if they are safe to prescribe to patients.
• In Part 1 of the RUBY study, the combination of
• Patients in the RUBY study were divided into subgroups according to their biomarker status. This allowed researchers to see if biomarker status could help determine how well patients with specific biomarkers would respond to the combination of
• This summary reports the results of the second data cut (the second time investigators looked at all of the data since the start of the study) of the RUBY study. At this time, researchers were looking specifically at how long patients lived and how safe the treatment was in patients who received
Footnotes
Acknowledgements
Writing and editorial support for this Plain Language Summary of Publication were coordinated by GSK and provided by Charlette Tiloke, PhD (writing support), Shannon Morgan-Pelosi, PhD, CMPP (writing support), and Mary C. Wiggin (editorial and submission support), of Ashfield MedComms, an Inizio company. Authors have authorized submission via a third party and have approved all statements and declarations.